Neochromosome, Inc.
Sarah Tsao, PhD, is a Senior Scientist II at Neochromosome, Inc. since May 2021, following a tenure as Senior Research Scientist at NYU Langone Health from October 2019 to May 2021. Previously, Sarah Tsao contributed to F1000 as an Associate Faculty Member, where significant achievements included reviewing critical scientific literature and selecting impactful antifungal research articles. At the Institut de recherche en immunologie et en cancérologie (IRIC), Sarah Tsao held roles as a Research Officer and Postdoctoral Research Fellow, specializing in innovative antifungal therapies and high-throughput screening. Additional experience includes serving as a visiting scientist at Johns Hopkins University, involvement in scientific juries, and organizing prominent scientific symposiums at IRIC. Sarah Tsao holds a PhD in Molecular Biology from McGill University, a Master of Science in Biochemistry, and a Bachelor's Degree in Science, both from the University of Otago.
This person is not in any teams
Neochromosome, Inc.
At Neochromosome, we enable biological engineering at a genome-scale. Our partners use our groundbreaking synthetic DNA and cell engineering services to investigate novel therapeutics, develop more sustainable products, and conduct pioneering scientific research. Neochromosome is uniquely suited to accelerate this work. Our first-in-class capabilities were developed to design, build, and test the world's first fully synthetic eukaryotic cells. Today, we offer our services and platform -- from highly automated synthesis of complex DNA to de novo design, synthesis, and delivery of chromosomes – to researchers around the world.